You are here: Industry Insights > Verona

News List

Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China prnasia
June 10, 2021
Verona Pharma plc and Nuance Pharma Limited, today announce that the companies have entered into an agreement granting Nuance Pharma, a Shanghai-based specialty pharmaceutical company, the rights to develop and commercialize ensifentrine in ...
Verona completes enrolment in pilot study of potential COVID-19 inhaler pharmatimes
January 18, 2021
UK-headquartered Verona Pharma has completed enrolment in its pilot study evaluating the efficacy of ensifentrine delivered via pressurised metered-dose inhaler (pMDI) formulation in patients hospitalised with COVID-19.
Verona begins pilot study of potential COVID-19 inhaler pharmatimes
September 17, 2020
Verona Pharma has kicked off a pilot study to investigate the efficacy and safety of ensifentrine delivered via pressurised metered-dose inhaler (pMDI) formulation in patients hospitalised with COVID-19.
Verona announces positive results for DPI form of COPD drug pharmaceutical-technology
August 06, 2019
UK-based Verona Pharma have announced the dry powdered inhaler (DPI) formulation of ensifentrine for chronic obstructive pulmonary disorder (COPD) has achieved all the endpoints in a Phase II trial.
Another EU patent for Verona in COPD drug pharmatimes
April 10, 2019
The European Patent Office has granted Verona pharma an additional key patent for its chronic obstructive pulmonary disease (COPD) drug, ensifentrine (RPL554)...
Verona initiates Phase II trial for COPD powder inhaler pharmatimes
December 18, 2018
Verona has announced the start of a Phase II clinical trial to evaluate the pharmacokinetic profile, efficacy and safety of a dry powder inhaler (DPI) formulation of RPL554, for use in patients with moderate to severe...
Verona’s RPL554 improves lung function in CF trial pharmatimes
March 05, 2018
London, UK-based Verona Pharma’s experimental phosphodiesterase therapy has hit targets in a mid-stage trial in patients with cystic fibrosis.